A Stanford / Snyder Lab Spin-out
The most comprehensive
long COVID autoantibody panel
A 120-autoantigen research panel built from over 2,500 screened publications and our own HuProt® proteome array data. Reserve your spot for early access.
Early Access
Muno Long COVID Research Panel
120 autoantigens · 5 symptom endotypes · Research Use Only
120 autoantigens across 5 endotypes · spinning structures show autoantibody-target complexes
The Science
How we built
the panel
The Muno long COVID research panel was designed by combining our own HuProt® human proteome array experiments with an extensive review of the published long COVID literature. We screened more than 2,500 publications across major biomedical databases and identified 167 peer-reviewed studies that specifically report on autoantibodies or autoantigens in long COVID / PASC cohorts. From these, we catalogued over 1,000 candidate biomarkers and used them — alongside our proprietary experimental findings — to design a focused panel of 120 autoantigens organized across 5 symptom-based endotypes: respiratory-mucosal, neuro-cognitive, sensory-cranial nerve, pain-musculoskeletal, and GI-visceral inflammation.
Many of our panel targets are supported by multiple independent published studies, including the classical GPCR autoantibodies (anti-β1/β2-adrenergic receptor, anti-muscarinic M3/M4 receptor, anti-AT1R), neuronal autoantibodies (anti-myelin basic protein, anti-MOG, anti-synapsin), and nuclear antigens (anti-SS-B/La, anti-MDA5), alongside novel targets identified through our original longitudinal HuProt screening. Literature evidence was graded using a standard evidence pyramid framework, prioritizing systematic reviews, large prospective cohorts, and case-control studies.
Databases: OpenAlex · PubMed · Semantic Scholar
Literature Foundation
Independent published work
that informs our panel
Targets on the panel converge with findings from multiple independent research groups. A selection of foundational studies we cite:
Cell · 2022
Su et al.
Multi-omic long COVID study establishing autoantibodies (including anti-IFN-α2) as a persistent signature.
Nature Communications · 2024
Jernbom et al.
Longitudinal new-onset autoantibody screen; anti-PCYT1B the only FDR-significant symptom association.
Autoimmunity Reviews · 2023
Seibert et al.
GPCR autoantibodies (anti-β1-AR, anti-M3R, anti-AT1R) correlated with neurocognitive and autonomic symptoms.
European Respiratory Journal · 2023
Son et al.
Anti-SS-B/La predictive of fatigue and dyspnoea with high specificity in long COVID cohorts.
Preprint · 2024
Visvabharathy et al.
Anti-MDA5 (IFIH1) and anti-Scl-70 correlated with poor cognitive performance in neuro-LC.
Journal of Medical Virology · 2024
Maes et al.
Anti-MBP, anti-MOG, anti-synapsin elevated in long COVID; associated with CFS and affective symptoms.
Frontiers in Immunology · 2025
Rodriguez-Perez et al.
Anti-AT1R significantly elevated in neuro-LC vs. convalescent and healthy controls.
International Journal of Molecular Sciences · 2022
Szewczykowski et al.
100% GPCR autoantibody seropositivity with functional agonistic activity in 42 LC patients.
A full bibliography is available on request. The complete panel target list will be published openly alongside the cohort data.
The Panel
120 autoantigens
across 5 endotypes
Each square represents a region of the panel — a curated autoantigen selection targeting one of five clinical endotypes established in the long COVID literature. The full target list publishes openly with the cohort data.
Respiratory-Mucosal · Neuro-cognitive · Sensory-Cranial Nerve · Pain-Musculoskeletal · GI-Visceral Inflammation
The Team
A Stanford / Snyder Lab
spin-out
Built by immunologists and engineers working at the intersection of precision immunology, long COVID research, and molecular diagnostics.
Why This Matters
An objective biological snapshot,
for a condition that's hard to see
Long COVID is often invisible in standard bloodwork. Patients are routinely told their labs look 'normal' even when they can barely get through a day. A comprehensive autoantibody profile provides an objective, quantified measurement of your immune state — something concrete to bring into conversations with your clinician, and a data point that contributes to the broader scientific effort to characterize long COVID as a measurable condition.
For patients navigating disability determinations, insurance claims, or clinical care, an objective biological measurement can serve as one additional piece of documentation alongside the rest of your medical record. We make no claim that this test alone establishes a diagnosis or supports a legal determination — it does not. But patients deserve access to the same objective data that researchers have.
This test is Research Use Only. It is not a diagnostic device and cannot by itself establish a clinical diagnosis or support a disability determination. Its value is as one more objective data point in your own understanding of your condition, and as a contribution to the broader research effort.
Understanding your immunology
Get a quantified readout of 120 autoantigens relevant to long COVID. Your own data, yours to keep.
Contributing to the research
De-identified data advances the broader effort to characterize long COVID as a measurable, researchable condition.
Supporting informed conversations
Bring an objective data point to conversations with your clinician, specialist, or research team.
Early Access · Reserve Your Spot
What you get
when you reserve
What's included
Home blood draw kit
Shipped to your door in the US. Return shipping included.
The 120-autoantigen research panel
Your sample processed on our full HuProt-based multiplex screen — the same assay we run in our research lab.
Individual PDF report
A detailed breakdown of your results across all 120 targets, organized by endotype. Yours to keep, yours to share with your clinician.
Clinical context summary
A plain-language summary written for you — not a lab datasheet. May provide context for conversations with your clinician; Research Use Only and not a diagnostic report.
Contribution to long COVID research
Your de-identified data contributes to the broader effort to characterize long COVID subtypes and inform future treatments.
Ongoing research updates
Quarterly email updates on findings, new targets, and cohort progress — without marketing. You can unsubscribe anytime.
Patient community access
Access to a private community of people participating in the research panel — share experiences, discuss results, and stay connected.
All deliverables are Research Use Only. See disclaimer at the bottom of the page.
Early Access Reservation
Early-access reservation price
- ·No payment required to reserve
- ·Price locked at $449 for early-access reservations
- ·Reservation includes everything in the left column
Reservation is free and non-binding. You'll only be charged when the panel ships and you confirm.
Question 1 of 5
Which best describes your background?
This helps us structure the cohort.
Open Research
What we're
contributing back
The long COVID community has been asked to contribute to research many times. These are the commitments we're making in return.
Open data release
De-identified cohort data released publicly alongside the preprint.
Preprint commitment
We commit to posting a preprint regardless of whether findings are positive or negative.
Public target list
The full 120-autoantigen target list will be published openly with the cohort data.
Common Questions
Questions
Is this a diagnostic test?
No. The Muno long COVID research panel is a Research Use Only (RUO) test. It is not FDA-approved as a diagnostic device and cannot by itself establish a clinical diagnosis or support a disability determination. It is an objective biological measurement that patients and researchers can use as one additional piece of information.
What's on the panel?
120 autoantigens organized across 5 long COVID symptom endotypes — respiratory-mucosal, neuro-cognitive, sensory-cranial nerve, pain-musculoskeletal, and GI-visceral inflammation. Targets were selected from over 2,500 screened publications and our own HuProt® proteome array experiments. The full target list will be published openly with the cohort data.
How does this differ from existing long COVID autoantibody work (Iwasaki, Putrino, LISTEN)?
Those studies are foundational and we cite them directly. Our panel is broader in target count, draws targets from their published findings, and commits to open data release alongside publication. The goal is not to compete with that work — it's to extend the panel coverage and make the assay available to patients and researchers.
Will the data be open?
Yes — de-identified cohort data will be released publicly, with timing committed to in the preprint.
Will you publish negative results?
Yes. The preprint commitment is unconditional on findings being positive.
Can I use the results for a disability claim?
This test is Research Use Only. It cannot on its own support a legal or clinical determination. However, the report provides an objective, quantified biological measurement that can be included as one piece of documentation alongside the rest of your medical record, at the discretion of your clinician.
How much does it cost and when will I be charged?
Early-access reservation price is $449 USD, down from a standard list of $1,000. Reserving your spot does not charge your card. You will only be charged when the panel ships and you confirm the order.
When will the panel ship?
We're finalizing timing and won't promise a date we can't hit. We expect to begin shipping early-access kits within the next few months. We'll email reservation holders with concrete dates as timing firms up.
How does the blood draw work?
A home collection kit ships to your door in the US. Return shipping is included. We're tracking demand internationally to expand to more countries.
What can I expect from this test — and what not?
You will receive a detailed readout of 120 autoantigen targets across 5 long COVID endotypes, with a plain-language summary of your results. This can give you an objective snapshot of your immune state and may surface patterns your standard bloodwork misses. What it cannot do: it cannot diagnose you, it cannot tell you what treatment to pursue, and it cannot on its own prove or disprove that you have long COVID. Autoantibody research in long COVID is still early — some targets on the panel are well-replicated across multiple studies, others are novel and exploratory. We will be transparent about which is which in your report. This is a research tool, not a clinical answer. If you are looking for a single test that explains everything, this is not it. If you are looking for one more objective data point in a condition where objective data is hard to come by, it may be worth your time.